Current Report Filing (8-k)
November 12 2019 - 3:09PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): November 7, 2019
BIOXYTRAN,
INC.
(Exact
Name if Business Issuer as specified in its Charter)
Nevada
|
|
001-35027
|
|
26-2797630
|
(State
or other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification Number)
|
233 Needham Street,
Suite 300
Newton MA, 02464
(Address
of principal executive offices, including zip code)
(617)
494-1199
(Registrant’s
telephone number including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 1 4a- 12 under
the Exchange Act (17 CFR 240.1 4a- 12)
☐
Pre-commencement communications pursuant to Rule 1 4d-2(b)
under the Exchange Act (17 CFR 240.1 4d-2(b))
☐
Pre-commencement communications pursuant to Rule 1 3e-4(c)
under the Exchange Act (17 CFR 240.1 3e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which
registered
|
|
|
|
|
|
Common
Stock, par value $0.001
|
|
BIXT
|
|
OTCQB
|
Item
1.01. Entry Into a Material Definitive Agreement.
On
November 7, 2019, Bioxytran, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “GS SPA”)
with GS Capital Partners, LLC (“GS”) for the purchase of a $125,000 convertible note (the “GS Note”),
with an original issue discount of $10,000 at an interest rate of 4% and due on November 7, 2020.
The
GS Note may be converted at any time after 180 days from the issue date into shares of Company’s common stock, par value
$.001 per share (the “Common Stock”) at a price equal to equal to the lesser of (a) $0.80 per share or (b) Sixty Five
percent (65%) of the lowest traded price (as reported by Bloomberg LP) of the Common Stock for the twenty (20) Trading Days immediately
preceding the date of the date of conversion of the GSS Note, subject to adjustment for certain penalties. The GSS Note may be
converted to up to a maximum of 4.99% of the issued and outstanding Common Stock of the Company. The GSS Note permits the Company
to pre-pay its obligations at a premium prior to maturity. The Company issued a warrant (the “Warrant”) to purchase
50,000 shares of its Common Stock with an exercise price of $2.00 per share expiring in 5 years with cashless exercise provisions.
The
foregoing description of the GS SPA, GS Note and Warrant does not purport to be complete and is qualified in its entirety by reference
to the full text of the form of the GS SPA, GS Note and Warrant, which are filed as Exhibits 10.35, 10.36 and 10.37 respectively
to this Current Report on Form 8-K and incorporated herein by reference.
On
November 11, 2019 the Company entered into a Consulting Services Agreement (the “FON Agreement”) with FON Consulting
LLC (“FON”) where FON will build market awareness through its family office network platform, events and sponsorships.
The term of the FON Agreement is six months.
As
compensation for its services, Bioxytran will issue FON 250,000 restricted shares of the Company’s Common Stock earned upon
the execution of the FON Agreement. The FON Agreement may be terminated by either party for cause. FON is an independent contractor.
The
foregoing description of the FON Agreement does not purport to be complete and is qualified in its entirety by reference to the
full text of the form of the FON Agreement, which is filed as Exhibit 10.38 to this Current Report on Form 8-K and incorporated
herein by reference.
Item
3.02 Unregistered Sales of Equity Securities
The
information provided in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
|
|
|
Number
|
|
Description
|
10.35
|
|
Form of Securities Purchase Agreement between GS Capital Partners, LLC and Bioxytran, Inc., dated No ember 7, 2019.
|
|
|
|
10.36
|
|
Form of 4% Convertible Note of Bioxytran, Inc. to GS Capital Partners, LLC. in the Principal Amount of $125,000 dated November 7, 2019
|
|
|
|
10.37
|
|
Form of Warrant to Purchase 50,000 shares of Common Stock of Bioxytran.
|
|
|
|
10.38
|
|
Form of Letter Agreement between FON Consulting, LLC and Bioxytran, Inc. dated November 11, 2019.
|
SIGNATURES
Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned hereunto duly authorized.
|
By:
|
/s/
David Platt
|
|
Name:
|
Dr.
David Platt
|
|
Title:
|
President
and Chief Executive Officer
|
|
|
|
Dated:
November 12, 2019
|
2
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bioxytran (QB) (USOTC:BIXT)
Historical Stock Chart
From Sep 2023 to Sep 2024